Go 2010.

Methods	Design: randomised controlled trial
Participants	Age: 18 to 60 years Randomised: ICS 16, systemic corticosteroid 17 Groups were reported to be comparable in terms of demographic variables except for oxygen saturation and corticosteroid use at baseline Inclusion criteria: adults with known bronchial asthma Exclusion criteria: status asthmaticus, COPD or corticosteroid intake in past 2 weeks
Interventions	Intervention: inhaled fluticasone (dose not stated) via ultrasonic nebuliser every 15 min with inhaled short‐acting beta2‐agonists Control: hydrocortisone 250 mg/mL IV single dose with inhaled short‐acting beta2‐agonists
Outcomes	Baseline demographic and clinical factors including vital signs, wheeze, RR, oxygen saturation, baseline PEF and mean rate of change in PEF post intervention
Notes	ICS versus systemic corticosteroid comparison Trial added in 2012 update
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Conference abstract – very limited information. It is stated that the patients were randomised to treatment
Allocation concealment (selection bias)	Unclear risk	Conference abstract – very limited information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Conference abstract – very limited information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Conference abstract – very limited information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Conference abstract – very limited information
Selective reporting (reporting bias)	Unclear risk	Conference abstract – very limited information